Some studies reported that nondisruptive mutations in TP53 can classify the response of NSCLC receiving first‐line EGFR‐TKIs treatment11, 23; nevertheless, Molina‐Vila et al.8 This evidence concerns the gene TP53 and non-small cell lung carcinoma.